Clinical trials: Digestive Organs--Cancer
Gastrointestinal Cancer, Gastric Cancer
NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers
The NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy…
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer
- Trial name
- NOMAD-GI (NCT07775859)
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectum Cancer, Adenocarcinoma
Adaptive Radiation Boost for Rectal Cancer
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.
- Trial name
- ARBOR (NCT07221058)
- Testing
- Adaptive Radiotherapy Boost
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fox Chase Cancer Center
Rectal Cancer
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer.
- Trial name
- NCT04380337
- Testing
- FOLFOXIRI, FOLFOX regimen, XELOX
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Stanford University
Stage II Rectal Cancer, Organ Preservation
Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery
A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam…
- Conditions
- Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III)
- Trial name
- MORPHEUS (NCT03051464)
- Testing
- Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost
- Where
- 4 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Rectal Neoplasms, Rectal Adenocarcinoma
A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer
This study aims to evaluate the safety and effectiveness of a combination treatment including a PD-1 inhibitor (serplulimab), oncolytic virus H101, short-course radiotherapy, and XELOX chemotherapy as total neoadjuvant therapy in…
- Trial name
- NCT07543848
- Testing
- Serplulimab, Oncolytic Virus H101, XELOX Chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chongqing University Cancer Hospital